Encision Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert H. Fries
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 6797 Winchester Circle Boulder CO United States of America 80301
- IPO Date
- Jan 2, 2004
- CIK
- 0000930775
- Website
- encision.com
- Similar Companies
- Business
- Encision Inc. is a medical device company specializing in the design, development, manufacture, and marketing of patented surgical instruments that enhance patient safety during minimally invasive surgeries. The company’s core product offerings include the AEM® (Active Electrode Monitoring) Shield™ laparoscopic surgical instruments, which comprise monopolar, bipolar, and cold laparoscopic instruments such as scissors, graspers, dissectors, fixed-tip electrodes, handles, and suction irrigation electrodes. These instruments are designed to prevent dangerous stray energy burns, a common surgical complication, by integrating the proprietary AEM technology that monitors and controls electrosurgical energy delivery to improve clinical outcomes and reduce surgical risks. Encision’s product portfolio emphasizes high performance, precision, and compliance with safety guidelines, with applications in a broad range of minimally invasive procedures primarily within the United States. Founded in 1995 and headquartered in Boulder, Colorado, Encision targets hospitals and surgical centers as its primary customers. Recently, the company has reported progress in increasing gross margins and operational efficiencies through investments in its sales channels and technology development. In the fiscal year 2025, Encision reported initiatives to create new service revenue streams via partnerships and collaboration opportunities to leverage its foundational AEM technology. A significant development includes a master services agreement signed with Vicarious Surgical Inc. in 2024, highlighting strategic business expansion efforts. Encision also announced ongoing development efforts culminating in new device launches, including a forthcoming product for the Ear, Nose, and Throat (ENT) surgical space, marking a business expansion into new clinical domains. The company completed a private placement funding round in 2025 to support its growth and innovation pipeline. Encision’s business operations and product innovation continue to focus on advancing surgical safety technology with an emphasis on minimally invasive procedures. The company maintains a portfolio of disposable and reusable laparoscopic surgical instrumentation that enhances ergonomics, reduces costs, and ensures patient protection against electrosurgical injuries. Encision’s strategic direction involves expanding its product range and market reach while reinforcing the technology’s competitive position in the medical device industry. The company remains publicly traded under the ticker ECIA and operates primarily in the U.S. healthcare market, with continued efforts to broaden its clinical applications and partnerships to support long-term growth and revenue diversification.
Encision Inc. Announces Halt of Stock Trading
Encision Inc. Announces Fiscal 2026 Fourth Quarter and Full Year Results
Encision Inc. Announces Fiscal 2026 Third Quarter Results
Encision Deregisters Common Stock
Encision Reports Second Quarter Fiscal Year 2026 Results
Encision Completes $500,000 Private Placement
Encision Reports First Quarter Fiscal Year 2026 Results
Encision Reports Fourth Quarter Fiscal Year 2025 Results
Encision Reports Third Quarter Fiscal Year 2025 Results
Encision Reports Second Quarter Fiscal Year 2025 Results
Encision Signs Master Services Agreement with Vicarious Surgical Inc.
Encision Reports First Quarter Fiscal Year 2025 Results
Encision Reports Fourth Quarter Fiscal Year 2024 Results
Encision Reports Third Quarter Fiscal Year 2024 Results
Encision Reports Second Quarter Fiscal Year 2024 Results
Encision Reports First Quarter Fiscal Year 2024 Results